Telomeres are considered potential anti-cancer targets. Most studies have focused on telomerase inhibition, but this strategy has largely failed in clinical trials. Direct disruption of the shelterin complex through TRF1 inhibition can block tumorigenesis in cancer mouse models by a mechanism that involves DNA damage induction and reduction of proliferation and stemness. Any anti-cancer target, however, must fulfill the requisite of not showing deleterious effects in healthy tissues. Here, we show that Trf1 genetic deletion in wild-type and cancer-prone p53-and Ink4Arf-deficient mice does not affect organismal viability and only induces mild phenotypes like decreased body weight and hair graying or hair loss, the skin being the most affected tissue. Importantly, we found that Trf1 is essential for tumorigenesis in p53-and Ink4Arf-deficient mice, as we did not find a single tumor originating from Trf1-deleted cells. These findings indicate a therapeutic window for targeting Trf1 in cancer treatment.
INTRODUCTION
Telomeres are heterochromatic structures at the ends of chromosomes that consist of tandem repeats of the TTAGGG sequence bound by a protective six-protein complex known as shelterin (Liu et al., 2004) . Shelterin encompasses TRF1, TRF2, RAP1, TPP1, TIN2, and POT1, and all of them, except for RAP1, are essential for telomere protection (De Lange, 2005; Martinez et al., 2010) . In particular, shelterin-bound telomeres protect chromosome ends from degradation and repair activities in this manner preventing end-to-end chromosome fusions and ensuring chromosome stability (De Lange, 2005) . Telomeres shorten throughout the lifespan of organisms associated to cell division owing to the so-called end replication problem, eventually jeopardizing tissue regeneration and organismal viability (Harley et al., 1990) . Telomere shortening can be compensated through de novo addition of telomeric repeats by telomerase, a reverse transcriptase composed of a catalytic subunit (TERT) and an RNA component (Terc) , which is used as template for the synthesis of telomeric repeats (Greider and Blackburn, 1985) . Telomerase is highly active in pluripotent stem cells during embryonic development; however, it is silenced in the majority of differentiated cells after birth, thus leading to telomere shortening with aging (Martínez and Blasco, 2011) . Telomeres can also be elongated by an alternative mechanism known as alternative lengthening of telomeres (ALT), which is based on homologous recombination (Bryan et al., 1997) .
Telomeres are considered as potential anti-cancer targets (Hanahan and Weinberg, 2011) . Cancer cells are known for their high proliferation rate, which induces a rapid telomere shortening followed by activation of DNA damage response (DDR) pathways that can lead to apoptosis or senescence. Any neoplastic cell should overcome these barriers to achieve an unlimited replicative potential, which in turn relies on telomere maintenance mechanisms (Hanahan and Weinberg, 2011) . In fact, more than 90% human tumors aberrantly over-express telomerase (Kim et al., 1994; Shay and Bacchetti, 1997) , whereas the remaining telomerase-negative tumors activate ALT (Bryan et al., 1997; Barthel et al., 2017) .
Most studies aiming to target telomeres in cancer have focused on telomerase inhibition as therapeutic approach to prevent telomere elongation in cancer cells (Harley, 2008) . Indeed, telomerase is heavily mutated in many different cancer types, and telomerase activation is seen in 90%-95% of all tumor types (Kim et al., 1994; Shay and Bacchetti, 1997; Joseph et al., 2010) .The most advanced anti-telomerase drug is GRN163L, also called imetelstat (Harley, 2008) . However, both mouse models and human clinical trials have shown the limitations of this strategy, as the anti-tumorigenic effect is only achieved when telomeres reach a critically short length (Gonzalez-Suarez et al., 2000; Perera et al., 2008) and this effect is lost in the absence of the p53 tumor suppressor gene, which is frequently mutated in cancer. In addition, telomerase inhibition may favor the activation of alternative telomere elongation mechanisms based on recombination as extensively shown in yeast and mammalian cells (Bryan et al., 1997; Barthel et al., 2017) .
Interestingly, not only telomerase but also shelterins are mutated in cancer. In this regard, we and others have found that POT1 is mutated in several types of sporadic and familial human cancers, including chronic lymphocytic leukemia (Ramsay et al., 2013) , familial melanoma (Robles-Espinoza et al., 2014; Shi et al., 2014) , Li-Fraumeni-like families with cardiac angiosarcomas (Calvete et al., 2015) , glioma (Bainbridge et al., 2015) , mantle cell lymphoma (Zhang et al., 2014) , and parathyroid adenoma (Newey et al., 2012) . These studies highlight the possibility of targeting the shelterin complex as a novel and promising strategy to target telomeres in cancer, which would lead to a rapid telomere dysfunction independently of telomere length, thus avoiding the shortcomings of telomerase inhibition. Indeed, several studies demonstrate that TRF1 inhibition could represent an alternative to telomerase to target telomeres more efficiently. TRF1 directly binds TTAGGG telomeric DNA where it is essential for telomere protection (De Lange, 2005; Martínez and Blasco, 2011) . Trf1 genetic deletion in vivo induces a persistent DDR at telomeres, which is sufficient to block cell division and induce apoptosis or senescence in several mouse tissues, independently of telomere length (Martínez et al., 2009; Beier et al., 2012; Schneider et al., 2013; Povedano et al., 2015) . Interestingly, TRF1 is over-expressed in adult stem cell compartments and in pluripotent stem cells, where it is essential to maintain tissue homeostasis and pluripotency, respectively (Boué et al., 2010; Schneider et al., 2013) . Over-expression of TRF1 has been also reported in several types of cancers such as renal cell carcinoma (Pal et al., 2015) and gastrointestinal tumors (Hu et al., 2010) . Furthermore, we have recently reported that induction of telomere uncapping by Trf1 genetic depletion or chemical inhibition can effectively block the growth of very aggressive and rapidly growing lung tumors in p53-deficient K-RasG12V mice, in a manner that is independent of telomere length (García-Beccaria et al., 2015) , thus further supporting that TRF1 could be a good anti-cancer target for aggressive tumors. We recently validated this hypothesis using glioblastoma (GBM) mouse models in which we demonstrated that Trf1 deletion blocks both tumor initiation and progression, showing great impact on mice survival (Bejarano et al., 2017) .
Given the promising results of TRF1 inhibition in two independent tumors types (i.e., lung cancer and glioblastoma), in the present work we aim to study the safety of long-term Trf1 genetic deletion in wild-type (WT) and cancer-prone mouse models.
RESULTS

Whole-Body Trf1 Deletion Does Not Affect Mouse Survival in the Context of Wild-Type or Cancer-Prone Mouse Models
Any potential anti-cancer target must fulfill the important requisite of not showing deleterious effects in healthy tissues or compromising organism viability. In line with this, we previously demonstrated that Trf1 whole-body deletion in adult mice does not impair organismal viability over a 6-month follow-up period and only leads to mild loss of cellularity in highly proliferative tissues (García-Beccaria et al., 2015; Bejarano et al., 2017) . However, potential lifelong adverse effects of Trf1 deletion in a healthy organism are still unknown. In addition, the long-term effects of Trf1 deletion and the associated telomere damage in cancer-prone mouse models are unknown. Thus, here we set to study the long-term effects of Trf1 whole-body deletion in three independent genetic backgrounds, including both WT and cancer-prone Ink4Arf À/À and p53 À/À backgrounds. To this end, we took advantage of the Trf1-inducible knockout mice previously described by us (Martínez et al., 2009) to generate the following independent mouse cohorts, which allow for Trf1 deletion upon tamoxifen administration in the diet: Trf1 lox/lox or Trf1 +/+ , hUBC-CreERT2, Ink4Arf À/À mice; Trf1 lox/lox or Trf1 +/+ , hUBC-CreERT2, p53 À/À mice; and Trf1 lox/lox or Trf1 +/+ , hUBC-CreERT2 mice. Next, we induced Trf1 deletion by administering tamoxifen in the diet at 6 weeks of age in the case of p53 À/À mice and at 10 weeks of age in the case of the Ink4rf À/À and WT cohorts ( Figure 1A ). The tamoxifen diet was started earlier in the case of p53 À/À mice owing to their shorter lifespan due to earlier tumor development (Jacks et al., 1994) . In all cases, the tamoxifen diet was maintained until the humane endpoint. At this time point (humane endpoint), we determined TRF1 levels in different mouse tissues by using immunofluorescence (Methods). In all genetic backgrounds, we observed that Trf1 lox/lox mice showed decreased TRF1 nuclear fluorescence foci in all the organs studied compared with control Trf1 +/+ mice ( Figures 1B-1D ). In addition, we confirmed 1E-1G) and PCR analysis (Figures S1E-S1G) in multiple organs from Trf1 +/+ and Trf1 lox/lox mice. Thus, longterm tamoxifen treatment can efficiently delete Trf1 in different adult mouse tissues.
To address whether long-term Trf1 deletion was affecting telomere length, we performed quantitative telomere fluorescence in situ hybridization (FISH) analysis in intestinal sections from Trf1 +/+ and Trf1 lox/lox mice. We observed that Trf1 deletion only caused a significant decrease in intestinal telomere length in Ink4Arf À/À mice ( Figure S2A ).
Interestingly, we found that Trf1 deletion did not significantly affect overall mouse survival in any of the genetic backgrounds studied (Ink4Arf-deficient, p53-deficient, and WT backgrounds) ( Figure 2A ). Trf1-deficient mice, however, showed skin abnormalities of different severities depending on the genetic background. In particular, in the Ink4Arf-deficient background, Trf1 deletion caused severe hair graying, whereas this was not observed in the p53 À/À background ( Figure 2B ). In the p53 À/À background, Trf1 deletion caused hair loss and skin wounds ( Figure 2B ). In the WT background, Trf1 deletion caused the most severe skin phenotype, including both hair graying and hair loss ( Figure 2B ), suggesting that loss of the tumor suppressors was partially rescuing the phenotypes induced by Trf1 deletion.
Longitudinal analysis of body weight also revealed that Trf1 abrogation in the Ink4Arf-deficient background caused a slight but significant decrease in body weight at older ages (6 months of age) only in females ( Figures 2C and 2D ). Interestingly, this phenotype was not observed in p53-deficient male or female mice ( Figures 2C and 2D ), again suggesting a less severe phenotype in the in p53-deficient mice than in the Ink4Arf-deficient background. Finally, as the case of the skin, the most severe weight phenotype was observed when Trf1 was deleted in the WT background, where both males and females showed a significant decrease in body weight, which was more severe in females ( Figures 2C and 2D ). In summary, full-body Trf1 deletion did not impair mouse viability in any of the studied genetic backgrounds, although we could observe mild phenotypes like decreased body weight and hair graying or hair loss, which were of different severities in the different genetic backgrounds.
Trf1 Genetic Deletion Induces Epithelial Abnormalities
To further characterize the cellular phenotypes induced by Trf1 deletion, we performed a full histological analysis of the different Trf1 lox/lox and Trf1 +/+ mouse cohorts. In the case of the Ink4Arf-deficient background, we did not see any significant pathologies in the intestine, bone marrow, and the liver of Trf1-deleted mice compared with control mice ( Figure 3A ). However, 85% of Trf1 lox/lox Ink4Arf À/À mice showed increased epithelial abnormalities compared with control mice ( Figure 3A ). We classified the skin lesions as ''non-tumoral'' and ''pre-neoplastic lesions.'' ''Non-tumoral'' lesions included degenerative lesions, i.e., atrophy in both epidermis and hypodermis, dermal fibrosis, follicular atrophy, and proliferative lesions, i.e., hyperkeratosis. The pre-neoplastic lesions included cell depolarization and nuclear atypia (i.e., anisocariosis, anisocytosis, and giant nuclei). We found that Trf1 deficiency in the Ink4Arf-deficient background caused a significant increase in both the percentage of mice with ''non-tumoral'' and ''pre-neoplastic'' lesions as well as in the number of these lesions per mouse ( Figures 3B-3E ). Although we did not find any overt intestinal pathologies in Trf1 lox/lox Ink4Arf-deficient mice, they showed a mild shortening of the intestinal microvilli ( Figure 3F ).
Interestingly, in the p53-deficient background, pathologies associated with Trf1 deletion were detected in a wider range of tissues including the skin, intestine, stomach, esophagus, and testes, although the differences reached statistical significance only in the skin and the intestine ( Figure 4A ). In the case of the skin, Trf1 deletion increased both the percentage of mice with ''non-tumoral'' and the ''pre-neoplasic'' lesions as well as the number of these lesions per mouse ( Figures 4B and 4C ). The most prevalent ''non-tumoral'' lesions included dermatitis, hyperkeratosis, and hyperplasia ( Figure 4D ). Regarding the pre-neoplastic lesions, Trf1 deletion increased the presence of dysplasia, cell depolarization, malignant hyperplasia, and nuclear atypia ( Figure 4E) . Similar results were observed in the intestine, the stomach, and the esophagus.
In particular, Trf1 deletion significantly increased the number of pre-neoplastic lesions in the intestine ( Figure 4F ), including dysplasia, cell depolarization, and nuclear atypia ( Figure 4G ). The same tendency was observed in stomach and esophagus ( Figures 4H and 4I ), although it did not reach statistical significance. Regarding the reproductive organs, we found that 18% of Trf1 lox/lox mice suffered from azoospermia in the testes or follicular atrophy in the ovaries ( Figure 4A ).
Finally, we also determined the effects of Trf1 deletion in a WT background. In this case, we observed a significant increase in pathologies in the skin and intestine, although it only reached statistical significance in the skin ( Figure 5A ). In fact, 100% of the Trf1-deficient mice showed an increase in skin pathologies (Figure 5A) . Interestingly, and contrary to the results obtained in cancer-prone models, all the pathologies found were ''non-tumoral'' ( Figures 5B and 5C ), including degenerative lesions like atrophy in both epidermis and hypodermis, dermal fibrosis and follicular atrophy, inflammatory lesions such as dermatitis, and proliferative lesion like benign hyperplasias and hyperkeratosis ( Figure 5D ).
In summary, Trf1 deletion increased the presence of non-tumoral lesions in the skin of Ink4Arf-deficient, p53-deficient, and WT mice. However, the increase in ''pre-neoplasic'' lesions was only observed in the absence of the tumor suppressors Ink4Arf and p53, but not when Trf1 was deleted in a WT background, suggesting that these tumor suppressors mediate some cellular effects of Trf1 deletion.
Trf1 Deletion Induces DNA Damage and Proliferation Defects, but Does Not Reduce Stem Cell Markers
Trf1 deletion has been previously shown to induce a persistent DDR at telomeres, which can lead to senescence or apoptosis depending on the cell type (Martínez et al., 2009; Beier et al., 2012; Schneider et al., 2013; Povedano et al., 2015) . Here, we set to address whether whole-body Trf1 deletion caused increased DNA damage in the context of WT and tumor-prone models studied here. Given that the most affected tissue was the skin, we quantified the percentage of cells positive for the gH2AX DNA damage marker in skin sections from Trf1 lox/lox and Trf1 +/+ mice in Ink4Arf-deficient, p53-deficient, and WT backgrounds by using immunohistochemistry (Methods). We found that in a Ink4Arf-deficient background, Trf1 lox/lox mice showed 12% gH2AX-positive skin cells compared with only 5% in the case of Trf1 +/+ mice ( Figure 6A) . Interestingly, in a p53-deficient background, Trf1 lox/lox mice showed up to 53% of the skin cells positive for gH2AX compared with 6% in the Trf1 +/+ controls ( Figure 6A ). In the case of a WT background, Trf1-deleted mice showed 18% of the skin cells positive for gH2AX positive compared with 3% in the Trf1 +/+ controls ( Figure 6A ). To study whether the DNA damage was stemming from telomeres, we determined the socalled telomere-induced foci (TIF), by performing immuno-FISH analysis with 53BP1 as a marker of DNA damage and the telomeric FISH probe to locate telomeres in skin sections. Again, Trf1 deletion only increased the percentage of cells with more than one TIF in the p53-deficient background ( Figure 6B ). Together, these findings suggest that p53 deficiency is allowing for the accumulation of DNA-damaged cells in the skin of Trf1 lox/lox mice, whereas these cells are less frequent in the skin of Ink4Arf-deficient and WT backgrounds, in agreement with the known role of p53 in signaling telomere-induced DNA damage Martínez et al., 2009 ).
Next, we set to address whether Trf1 deletion also resulted in cell proliferation defects in the skin. To this end, we quantified the percentage of cells positive for the Ki67 proliferation marker by using immunohistochemistry in skin sections from the different mouse cohorts. In the Ink4Arf-deficient background, we found a severe decrease in proliferation with only 10% of the basal layer cells positive for Ki67 compared with more than 20% in the control mice ( Figure 6C ). In contrast, in the absence of p53, Trf1 lox/lox mice showed a marked increase in proliferation reaching 60% of the basal layer cells being positive for Ki67 compared with 20% in the control counterparts ( Figure 6C ). In the WT background, however, we did not see significant differences in proliferation between the Trf1-deleted and control counterparts ( Figure 6C ). Again, these results suggest that the p53 tumor suppressor represents a stronger barrier than the Ink4Arf tumor suppressor to prevent the proliferation of cells deficient for Trf1 and with increased DNA damage, which in turn may favor the increased pre-neoplastic lesions in these backgrounds.
Finally, we determined whether Trf1 deletion was affecting known skin stem cell makers. To this end, we quantified the percentage of cells positive for the Sox9 skin stem cell marker by using immunohistochemistry in skin sections from Trf1 +/+ and Trf1 lox/lox mice. However, we did not observe significant differences in Sox9-positive cells in Trf1-deleted mice from any of the different genetic backgrounds ( Figure 6D ). As an independent tissue, we determined the percentage of Sox2-positive cells (a marker of neural stem cells) by immunohistochemistry in the brain, and again we did not observe any differences in the number of Sox2positive cells between Trf1 +/+ and Trf1 lox/lox mice in the different genetic backgrounds ( Figure S3A ).
Tumors Appearing in Trf1-Deleted Mice Are Escapers and Express the TRF1 Protein
The absence of both the Ink4Arf and the p53 tumor suppressors has been widely linked to the appearance of spontaneous tumors in mice, including histiocytic sarcomas (HS), sarcomas, or lymphomas (Jacks et al., 1994; . On the other hand, we have recently demonstrated that Trf1 deletion has an antitumorigenic effect in the context of oncogene-driven tumors in mice by using both lung cancer and glioblastoma mouse models (García-Beccaria et al., 2015; Bejarano et al., 2017) . However, even though Trf1 deletion has an anti-tumorigenic effect in oncogene-induced tumor models, it is also conceivable that DNA damage induced by Trf1 deletion could promote tumorigenesis in the context of tumor suppressor-deficient mouse models. To explore this possibility, we studied spontaneous tumorigenesis in Trf1 lox/lox and Trf1 +/+ mice, in both Ink4Arf-and p53-deficient backgrounds. To this end, we followed mice throughout their entire lifespan and studied the onset and severity of the tumors that appeared.
In a Ink4Arf background, Trf1 deletion did not alter the percentage of mice with tumors ( Figure 7A ) or the tumor onset ( Figure 7B ). Interestingly, when looking at particular tumor types, we observed that Trf1-deleted mice showed a higher incidence of lymphomas (up to 66%) and a lower incidence of HS and sarcomas, although the two latter ones did not reach statistical significance (Figures 7C and S4A ). Although these findings may suggest increased tumorigenesis in the absence of Ink4Arf, analysis of TRF1 protein levels in tumors by immunofluorescence revealed that all the lymphomas and HS analyzed in Trf1-deficient mice showed normal TRF1 protein levels, indicating that they did not originate from Trf1-deleted cells ( Figure 7D ). The fact that we did not find a single tumor lacking TRF1 expression indicates that TRF1 deficiency impedes tumorigenesis in Ink4Arf-deficient background.
In the case of the p53-deficient background, Trf1-deleted mice reduced the percentage of mice with tumors from 90% (Trf1 +/+ ) to 68% (Trf1 lox/lox ) ( Figure 7E ), although this difference did not reach statistical significance. Similarly, we did not observe any differences in tumor onset between Trf1 +/+ and Trf1 lox/lox mice ( Figure 7F ). When looking at individual tumor types, we observed a tendency to show decreased thymic lymphomas and sarcomas in the Trf1 lox/lox mice ( Figures 7G and S4B ), although the difference did not reach statistical significance. In contrast, we observed a significant increase in skin carcinomas in Trf1 lox/lox mice (Figures 7G and S4B ). However, TRF1 immunofluorescence analysis indicated that all the tumors appearing in Trf1 lox/lox mice were escapers, as no differences were found in TRF1 protein levels compared with the Trf1 +/+ mice ( Figure 7H ). Note that for skin carcinomas we used normal skin of Trf1 +/+ mice as control as these types of tumors were not found in control mice.
These findings indicate that Trf1 deficiency completely blocks tumorigenesis in the context of mice deficient for two major tumor suppressors, Ink4Arf and p53.
DISCUSSION
Therapeutic strategies based on telomerase inhibition have been the focus of cancer treatments for some years, as telomere maintenance above a minimum length is necessary for cancer cell growth (Kim et al., 1994; Hanahan and Weinberg, 2011 clinical trials with telomerase inhibitors have shown limitations, most likely owing to the fact that a telomerase inhibitor would be only effective when telomeres are short and tumors are heterogeneous in terms of telomere length as well as can activate telomerase-independent mechanisms for telomere length maintenance or ALT Greenberg et al., 1999; Gonzalez-Suarez et al., 2000; Parkhurst et al., 2004; Perera et al., 2008; Middleton et al., 2014) .
We have recently proposed an alternative strategy for targeting the telomeres independently of telomere length by directly targeting the telomere-protective complex shelterin through TRF1 inhibition. TRF1 is an essential component of shelterin that directly binds TTAGGG telomeric DNA repeats (De Lange, 2005; Martínez and Blasco, 2011) . Trf1 genetic deletion in vivo induces a persistent DDR at telomeres, which is sufficient to block cell division and induce apoptosis or senescence in several mouse tissues (Martínez et al., 2009; Beier et al., 2012; Schneider et al., 2013; Povedano et al., 2015) . Interestingly, induction of telomere uncapping by Trf1 genetic depletion or TRF1 chemical inhibition can effectively block the growth of very aggressive and rapidly growing lung tumors in p53-deficient K-RasG12V mice, in a manner that is independent of telomere length (García-Beccaria et al., 2015) , as well as can block both tumor initiation and progression in glioblastoma mouse models (Bejarano et al., 2017) .
Any potential anti-cancer target must fulfill the important requisite of not showing deleterious effects in healthy tissues or compromising organism viability. In line with this, we had previously demonstrated that short-term Trf1 full-body deletion does not impair organism viability or cognitive functions and only affects slightly the highly proliferative tissues (García-Beccaria et al., 2015; Bejarano et al., 2017) . However, the long-term effects of Trf1 deletion are still unknown.
Here we set to address the long-term effects of Trf1 whole-body deletion in three different genetic backgrounds, including WT mice and the cancer-prone Ink4Arf À/À and p53 À/À mouse models. We show that full-body Trf1 deletion does not impair mouse viability in any of the studied genetic backgrounds, although we could observe mild phenotypes like decreased body weight and hair graying or hair loss, which were more severe in the WT background. In all the studied genetic backgrounds the most affected tissue was the skin. In fact, Trf1 deletion increased the presence of ''non-tumoral,'' mainly degenerative, lesions in the skin in all the studied backgrounds. Interestingly, we also observed an increase in pre-neoplastic lesions, but only in the absence of the tumor suppressors Ink4Arf and p53. At the cellular level, we observed that Trf1 deletion induced different degrees of DNA damage in the skin of all genetic backgrounds although we only observed increased proliferation in the case of the p53-deficient background, in line with the known role of p53 in signaling proliferation arrest in the presence of dysfunctional telomeres. Importantly, we did not observe significantly decreased stem cell markers in the skin or the brain upon conditional Trf1 deletion, suggesting that tissue homeostasis is largely preserved upon Trf1 deletion, in agreement with normal survival of Trf1-deleted mice in all genetic backgrounds.
We previously showed that Trf1 deletion can block the growth of oncogene-driven, aggressive lung and glioblastoma tumors by inducing DNA damage at chromosome ends (García-Beccaria et al., 2015; Bejarano et al., 2017) . However, it was still unclear whether persistent Trf1 deletion in the absence of an oncogenic driver could eventually lead to a high genomic instability and promote tumorigenesis. To explore this idea, we studied spontaneous tumorigenesis in Trf1 lox/lox and Trf1 +/+ mice, in both Ink4Arf-and p53-deficient backgrounds. The absence of both the Ink4Arf and the p53 tumor suppressors has been widely linked to the appearance of spontaneous tumors in mice, including HS, sarcomas, or lymphomas (Jacks et al., 1994; . The results described here clearly indicate that Trf1 deletion does not increase the percentage of mice with tumors in the absence of the tumor suppressors, although for certain tumor types, like lymphomas in the Ink4Arf-deficient background and skin carcinomas in the case of the p53-deleted mice, we found an increased incidence upon Trf1 deletion. However, analysis of TRF1 protein levels in these tumors revealed that they were not deficient for TRF1 as they showed normal TRF1 protein levels, indicating that they did not originate from Trf1-deleted cells. The fact that no tumors lacking TRF1 expression were found suggests that TRF1 is essential for tumorigenesis in both Ink4Arf-deficient and p53-deficient backgrounds.
In light of these findings, one could argue that TRF1 inhibition in cancer could be advantageous compared with classical chemotherapies that are known to induce severe DNA damage, as well as induction of premature aging effects and of secondary tumors. In summary, these findings support that there is a therapeutic window for targeting TRF1 in cancer treatment.
Limitations of the Study
The limitation of this study is that Cre-mediated Trf1 deletion is not 100% in every organ, as reported by the immunofluorescence data. Thus, it should be considered that the observed phenotype is the consequence of a 50%-70% Trf1 deletion.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. Ink4Arf -/-p53 -/-WT Trf1 lox/lox mice (Martínez et al., 2009) were crossed with a mouse strain carrying 29 ubiquitously expressed, tamoxifen-activated recombinase, hUBC-CreERT2 30 (Ruzankina et al., 2007) to generate Trf1 lox/lox or Trf1 +/+ , hUBC-CreERT2 mice. These 31 mice were further crossed with Ink4Arf -/- and p53 -/- (Jacks et al., 32 1994 ) mouse lines to generate Trf1 +/+ or Trf1 lox/lox , hUBC-CreERT2, Ink4Arf -/and 33 Trf1 +/+ or Trf1 lox/lox , hUBC-CreERT2, p53 -/mice. These mice were fed ad libitum with 34 tamoxifen containing diet for long-term, starting at 6 weeks of age for p53-deficient 35 background and 10-weeks of age for Ink4Arf-deficient and wild type backgrounds. 
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